|
Patient
Satisfaction with Abacavir-Lamivudine Fixed-dose Combination (FDC)
Tablet Once daily (QD) Compared with Abacavirand Lamivudine Twice-daily
s
Patient satisfaction was evaluated, and the
effect of dosing symmetry explored, as part of a randomized open-label
study (ESS30008) comparing abacavir/lamivudine/
ABC/3TC fixed-dose combination (Epzicom) once-daily
(QD) and
ABC/3TC twice-daily (BID) plus a third agent. Results are from the
final 48-week analysis.
Results
·
Baseline
satisfaction was high and comparable in both treatment groups (p=0.49).
·
At Week
48, there were trends towards greater improvement in satisfaction
with treatment convenience (p= 0.041) and treatment flexibility
(p=0.074) in the FDC group.
·
The effect
of dosing symmetry was statistically significant for 6 HIVTSQc items
(satisfied with current treatment, treatment demands, treatment
convenience, treatment flexibility, treatment fits lifestyle and
satisfied to continue treatment; p<0.05 for each).
·
Patients
on a pure QD regimen showed markedly greater improvements in satisfaction
versus those on a mixed regimen.
According to the authors, “Satisfaction with treatment convenience
and flexibility were enhanced by switching patients from ABC BID+3TC
BID to ABC/3TC FDC (Epzicom) once daily.
Symmetrical
dosing regimens appear to increase patient satisfaction.”
GlaxoSmithKline, Research Triangle Park,
NC, United States of America, Social Security Hospital, Panama City,
Panama, Orlando Immunology Center, Orlando, FL, USA.
08/08/05
Reference
M Watson and others. Patient satisfaction with abacavir
(ABC)-lamivudine (3TC) fixed dose combination (FDC) tablet once
daily (QD) compared with ABC and 3TC twice daily (BID) in HIV-1
infected patients (ESS30008). Abstract WePe6.3C08 (poster). Program and Abstracts of the 3rd IAS Conference
on HIV Pathogenesis and Treatment. July 24-27, 2005. Rio de Janeiro,
Brazil.
|
